Abivax's Phase 3 ABTECT Maintenance Trial Of Obefazimod Met Primary Endpoint Of Clinical Remission And All Key Secondary Endpoints At Week 44 In Ulcerative Colitis

뉴스 본문을 불러오고 있어요.

Abivax's Phase 3 ABTECT Maintenance Trial Of Obefazimod Met Primary Endpoint Of Clinical Remission And All Key Secondary Endpoints At Week 44 In Ulcerative Colitis | 웨이프 WAPE

Abivax's Phase 3 ABTECT Maintenance Trial Of Obefazimod Met Primary Endpoint Of Clinical Remission And All Key Secondary Endpoints At Week 44 In Ulcerative Colitis

기사 요약

관련 종목

댓글 —